Demystifying Medicine Video



Since its emergence in December 2019, the world has been dealing with COVID-19, which was officially declared a global pandemic by the World Health Organization in March. As the virus continues to spread and infect people worldwide, research is constantly underway to develop new antiviral drugs to help treat patients.

On October 22, 2020, the FDA approved the first antiviral drug for treating COVID-19, called Remdesivir. Remdesivir works by targeting RNA polymerase and therefore inhibiting the viral RNA replication of SARS-CoV-2,. This antiviral holds a great deal of promise and is an exciting discovery in the field of medicine.

[Please complete our feedback form]





References
  • About COVID-19. (n.d.). Retrieved October 28, 2020, from http://www.bccdc.ca/health-info/disea...
  • Cao, Y., Deng, Q., & Dai, S. (2020). Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease, 35, 101647. https://doi.org/10.1016/j.tmaid.2020....
  • Cohen F. S. (2016). How Viruses Invade Cells. Biophysical journal, 110(5), 1028–1032. https://doi.org/10.1016/j.bpj.2016.02...
  • Coronavirus disease (COVID-19). (2020, October 10). Retrieved October 28, 2020, from https://www.canada.ca/en/public-healt...
  • FDA. (2020, October 22). FDA approves first treatment for COVID-19. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press...
  • Gordon, C. J., Tchesnokov, E. P., Woolner, E., Perry, J. K., Feng, J. Y., Porter, D. P., & Götte, M. (2020). Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. The Journal of biological chemistry, 295(20), 6785–6797. https://doi.org/10.1074/jbc.RA120.013679
  • Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., … Flanigan, T. (2020). Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 382(24), 2327–2336. https://doi.org/10.1056/nejmoa2007016
  • Hendaus, M. A. (2020). Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): a simplified summary. Journal of Biomolecular Structure and Dynamics. https://doi.org/10.1080/07391102.2020...
  • Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., …
  • Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20...
  • Razonable R. R. (2011). Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clinic proceedings, 86(10), 1009–1026. https://doi.org/10.4065/mcp.2011.0309
  • Saha, A., Sharma, A. R., Bhattacharyac, M., Sharma, G., Lee, S., & Chakrabortya, C. (2020). Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more. Archives of Medical Research, 51(6), 585-586. https://doi.org/10.1016/j.arcmed.2020...
  • Vardanyan, R., & Hruby, V. (2006). Antiviral Drugs. Synthesis of Essential Drugs, 549–557. https://doi.org/10.1016/b978-04445216...
  • Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 181(2), 281–292.e6. https://doi.org/10.1016/j.cell.2020.0...
  • Wilt, T. J., Kaka, A. S., Macdonald, R., Greer, N., Obley, A., & Duan-Porter, W. (2020). Remdesivir for Adults With COVID-19. Annals of Internal Medicine. https://doi.org/10.7326/m20-5752
  • Yin, W., Mao, C., Luan, X., Shen, D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., Chang, S., Xie, Y., Tian, G., Jiang, H., Tao, S., Shen, J., Jiang, Y., Jiang, H., Xu, Y., … Xu, H. E. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science, 368(6498), 1499-1504. https://doi.org/10.1126/science.abc1560



Accessibility for Ontarians With Disabilities Act (AODA)

 

The Faculty of Health Sciences is committed to providing a website that is accessible to the widest possible audience. If there is an accessibility issue with this website, please contact us at fhsweb@mcmaster.ca.